Brian V. Elliott joins Arev Life Sciences Global Corporation

VANCOUVER, BC / TheNewswire/ April 192022 / AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation today announced the appointment of Brian V. Elliott, B Comm to its Board of Directors.

In Pursuit of Innovative Global Health Solutions, AREV Life Sciences Global Corporation Adds Brian V. Elliott, within its board of directors.

Brian V. Elliott is an international strategist and leader with over 35 years of experience in leadership positions in the pharmaceutical industry and public health-related sectors. He provided 10 years of service with the Irish Government’s Industrial Development Authority in Ireland, France and Lesotho.

Brian entered the pharmaceutical industry serving as International Sales Manager at Norton Healthcare Generics based in Ireland and the UK, leading their Ireland-based manufacturing operations. He assumed the position of Director of Janssen Pharmaceutica NV in charge of China, then was appointed Director of International Trade, Janssen Africa, Middle East, West Asia.

He was recruited by the Belgian biotechnology company Tibotec-Virco NV, as Senior Vice President, Corporate Alliances and Business Development. Brian was also CEO of Tibotec Virco, Ireland.

Brian V. Elliott established Axios International Consultants Ltd in Ireland and served as Chairman of the organization for 5 years during which time he undertook numerous health-related projects in developing countries including:

  • United Nations Program on HIV/AIDS (UNAIDS) negotiator with the pharmaceutical industry on access to antiretrovirals, where he co-designed the UNAIDS Medicines Access Initiative and implemented projects pilots in Vietnam, Chile, Uganda and Ivory Coast.

  • Advisor to the Danish Ministry of Foreign Aid on international HIV/AIDS policy.

  • The design and implementation of several global access initiatives, including:

    • Bristol Myers Squibb – Secure the Future project in South Africa,

    • Abbott – Step Forward for Children Project in Tanzania and Burkina Faso, Abbott

    • Gilead – Viread Global Donation Program

    • Pfizer – Pfizer diflucan donation project

    • Roche-Blue Skies project in Southern Africa

    • Glaxo Wellcome- differentiated pricing for developing countries.

In 2008, Brian was appointed Executive Director of the Medical Transparency Alliance (MeTA), an alliance of the UK Department for International Development, the World Bank and the World Health Organization (WHO) aimed at increasing transparency. access to essential drugs in 7 pilot countries (Peru, Jordan, Kyrgyzstan, Uganda, Zambia, Ghana and the Philippines). He was also a member of the Affordable Medicine Facility for Malaria (AMFm) expert advisory panel on the review of the project assessment process.

Recently, Brian has advised a number of large pharmaceutical companies establishing programs to provide global access to medicines working closely with Johnson & Johnson Global Public Health Group and other multinational companies. These efforts include reporting to companies, agencies and foundations on critical aspects of HIV/AIDS treatment in developing countries.

Projects in these areas include: working closely with Indian manufacturers of antiretroviral drugs to advocate with the Global Fund and PEPFAR to change their procurement processes, reporting. for the United Nations Industrial Development Organization (UNIDO), UNAIDS and WHO on security of supply of HIV/AIDS commodities, reviewing the Appropriate Use Criteria Program ( AUC)/UNIDO Africa Pharmaceutical Manufacturing Plan for WHO, and providing strategies for the implementation of the WHO/UNIDO Africa Pharmaceutical Manufacturing Plan.

Brian continues to advise Johnson & Johnson Global Public Health Group and several other international pharmaceutical companies on the establishment of Global Access to Medicines programs in developing countries. He compiled the WHO Procurement and Supply Management (PSM) Profile Update, which updated PSM profiles for 85 countries to assess the deployment status of CD4 and VL technology .

He addressed the United Nations Assembly Special Meeting on the looming HIV treatment crisis and trained and advised a coalition of 11 Indian generic drug manufacturers and led discussions among them, the plan to president’s emergency for aids Relief (PEPFAR) and the Global Fund to address perceived inequities in the antiretroviral supply system in low- and middle-income countries, market dynamics and supply security risk.

He is currently managing the establishment of clinical trials of 2 new drugs to treat NCDs and 2 Covid vaccine candidates in Kenya and advising governments in sub-Saharan Africa.

Additionally, the Company is pleased to announce that the Company has issued 150,000 stock options to directors, officers and consultants of the Company at a price of $0.22 for a period of 5 years from the date of issue. These options will vest immediately.

For more information, contact Mike Withrow, [email protected] 778-929-6536. For more information, visit www.arevlifesciences.com.

On behalf of the Council,

mike withrow
CEO and Director

ABOUT AREV Life Sciences Global Corp.

AREV Life Sciences Global Corp. is a fully integrated, publicly traded, early-stage life sciences company dedicated to delivering therapeutic public health interventions through unique compound extraction, discovery, innovation and successful collaborations. The companys leadership drives discovery programs for the clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system. AREV invests in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for the associated chronic neglected comorbidities and innovations in human nutrition. AREV is dedicated to designing and delivering innovations in rational drug design, driven by presenting the global epidemiological characteristics of the multiple challenges in international human and animal health. AREV is a member of BIOTECanada and the Biotechnology Innovation Organization (BIO).

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED NOR ACCEPTS RESPONSIBILITY FOR THE SUITABILITY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements contained herein, other than statements of historical fact, should be considered forward-looking. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include market prices, mining and exploration success, the continued availability of capital and financing, and general economy, market or business. There can be no assurance that such statements will prove to be accurate and, therefore, readers are urged to rely on their own assessment of these uncertainties. We undertake no obligation to update forward-looking statements, except as required by applicable law. This press release contains forward-looking statements. Use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and the like similar expressions is intended to identify -looking statements. Although the Company believes that the expectations and assumptions on which forward-looking statements are based are reasonable, undue reliance should not be placed on forward-looking statements as the Company cannot guarantee that they will prove to be accurate. Because forward-looking statements address future events and conditions, they, by their very nature, involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and various risk factors discussed in the Company’s reports Management‘s Discussion and Analysis under the company profile on www.sedar.com.

Luisa D. Fuller